Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
ZBH · NYSE · Healthcare
Fundamental quality
63
out of 100
Zimmer Biomet Holdings, Inc. earns a fundamental-quality score of 63 out of 100, profiling it as a company of reasonable quality. Its score rests mainly on its financial strength (net debt 3.08× EBITDA). Its weakest area is its profitability (net margin 9.1%). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Zimmer Biomet makes knee and hip implants: it is a world leader in joint replacement, the business of restoring mobility to an aging population. It also sells surgical robots that assist orthopedic surgeons in the operating room.
EPS growth: 18% · Revenue growth: 6.2%
Net margin: 9.1% · ROE: 6% · ROIC: 5%
Net debt/EBITDA: 3.08x · FCF: 17.3%
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its profitability drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 6,128 | -139 | 1,093 | 7,324 |
| 2021 | 6,827 | 402 | 1,356 | 6,722 |
| 2022 | 6,940 | 231 | — | 5,324 |
| 2023 | 7,394 | 1,024 | 1,291 | 5,384 |
| 2024 | 7,679 | 904 | 1,296 | 5,679 |
| 2025 | 8,232 | 705 | 1,473 | 6,927 |
Between 2020 and 2025, revenue went from $6,128M to $8,232M (+34%) and net income went from -$139M to $705M (+608%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the quarter ended March 31, 2026, versus the quarter ended March 31, 2025 (SEC filings):
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$0.96
per share, yearly
27% of earnings
Payout
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Zimmer Biomet Holdings, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Zimmer Biomet Holdings, Inc. a good company to invest in?
In terms of business quality, Zimmer Biomet Holdings, Inc. scores 63 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Zimmer Biomet Holdings, Inc. a profitable company?
Zimmer Biomet Holdings, Inc. is profitable, with a net margin of 9.1%, though a thin one.
Does Zimmer Biomet Holdings, Inc. have a lot of debt?
Yes, its leverage is high: net debt is 3.08 times its EBITDA.
Is Zimmer Biomet Holdings, Inc. growing?
Its revenue has grown 6.2% annualized in recent years and its earnings per share 18%, and without interruption since 2020.
Does Zimmer Biomet Holdings, Inc. generate cash?
Yes. It converts about 17.3% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Labcorp (LH) · Quest Diagnostics (DGX) · Insulet (PODD) · Edwards Lifesciences (EW) · Molina Healthcare (MOH) · Medline (MDLN) · see more →
The best Healthcare stocks by our model →
Compare Zimmer Biomet Holdings, Inc. with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Zimmer Biomet Holdings, Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.